Related Experiment Videos
[Determination of circulating ectopic beta HCG in solid tumors (author's transl)]
Pathologie-Biologie
|March 1, 1981
Summary
Elevated beta subunit of human chorionic gonadotropin (betaHCG) was found in 5.2% of non-trophoblastic carcinoma patients. This finding may indicate a worse prognosis in metastatic cancers.
Area of Science:
- Oncology
- Biochemistry
- Tumor Markers
Context:
- Investigated the role of beta subunit of human chorionic gonadotropin (betaHCG) as a potential tumor marker.
- Analyzed serum samples from 1,850 patients with non-trophoblastic carcinomas.
- Assessed the incidence and significance of elevated betaHCG levels in various malignancies.
Purpose:
- To determine the prevalence of elevated betaHCG in non-trophoblastic carcinomas.
- To evaluate the diagnostic utility of betaHCG in conjunction with CEA.
- To explore the prognostic implications of elevated betaHCG in cancer patients.
Summary:
- Elevated betaHCG plasma levels were detected in 5.2% of patients with non-trophoblastic carcinomas.
- Highest incidences of elevated betaHCG were observed in bladder, lung (squamous cell), pancreatic, and colorectal carcinomas.
- BetaHCG determination did not significantly improve diagnostic sensitivity over CEA, except in bladder carcinomas.
Impact:
- Suggests that elevated ectopic betaHCG may be associated with a poorer prognosis in metastatic cancers.
- Highlights betaHCG as a potential, albeit limited, biomarker in specific non-trophoblastic malignancies.
- Warrants further investigation into the mechanisms linking ectopic betaHCG production to cancer progression and survival.